"This is a significant milepost in our journey of serving 5 million patients by FY22 and crossing a revenue milestone of $1 billion," said Christiane Hamacher, CEO, Biocon Biologics.from Moneycontrol Business News https://ift.tt/33pTd7m
Tuesday, November 26, 2019
USFDA approves Biocon drug Pegfilgrastim from new Bengaluru facility
"This is a significant milepost in our journey of serving 5 million patients by FY22 and crossing a revenue milestone of $1 billion," said Christiane Hamacher, CEO, Biocon Biologics.from Moneycontrol Business News https://ift.tt/33pTd7m
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment